Cargando…

Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study

COVID-19 is an emerging infectious disease capable of causing severe pneumonia. We aimed to characterize a group of critically ill patients in a single-center study. This was a retrospective case series of 23 patients with confirmed COVID-19-related critical illness in the intensive care unit (ICU)...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jian, Dong, Yong-Quan, Yin, Jie, He, Guojun, Wu, Xiaoxin, Li, Jianping, Qiu, Yunqing, He, Xuelin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328989/
https://www.ncbi.nlm.nih.gov/pubmed/32590819
http://dx.doi.org/10.1097/MD.0000000000021012
_version_ 1783552829716168704
author Liu, Jian
Dong, Yong-Quan
Yin, Jie
He, Guojun
Wu, Xiaoxin
Li, Jianping
Qiu, Yunqing
He, Xuelin
author_facet Liu, Jian
Dong, Yong-Quan
Yin, Jie
He, Guojun
Wu, Xiaoxin
Li, Jianping
Qiu, Yunqing
He, Xuelin
author_sort Liu, Jian
collection PubMed
description COVID-19 is an emerging infectious disease capable of causing severe pneumonia. We aimed to characterize a group of critically ill patients in a single-center study. This was a retrospective case series of 23 patients with confirmed COVID-19-related critical illness in the intensive care unit (ICU) of a hospital in Hangzhou Zhejiang Province between January 22 and March 20, 2020. Of the 23 critically ill patients, the median age was 66 years (interquartile range [IQR] 59–80 years). The median time from disease onset to ICU admission was 10 days (IQR 6–11 days), to mechanical ventilation (MV) was 11 days (IQR 7.75–13 days), to artificial liver plasma exchange was 12 days (IQR 9.75–14.75 days), and to extracorporeal membrane oxygenation (ECMO) was 22 days (IQR 17.5–30 days). Nine patients required high flow oxygen. Fourteen patients received MV. Six required ECMO. Nine received artificial liver plasma exchange. Mortality was 0 at day 28. Mortality was 0 at day 28 in our single-center study. Extracorporeal membrane oxygenation reduced the requirements for ventilator support. Artificial liver plasma exchange significantly reduced inflammatory cytokine levels. These supportive therapies helped to extend the patients’ survival times and increase the chance of follow-up treatments.
format Online
Article
Text
id pubmed-7328989
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-73289892020-07-09 Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study Liu, Jian Dong, Yong-Quan Yin, Jie He, Guojun Wu, Xiaoxin Li, Jianping Qiu, Yunqing He, Xuelin Medicine (Baltimore) 4900 COVID-19 is an emerging infectious disease capable of causing severe pneumonia. We aimed to characterize a group of critically ill patients in a single-center study. This was a retrospective case series of 23 patients with confirmed COVID-19-related critical illness in the intensive care unit (ICU) of a hospital in Hangzhou Zhejiang Province between January 22 and March 20, 2020. Of the 23 critically ill patients, the median age was 66 years (interquartile range [IQR] 59–80 years). The median time from disease onset to ICU admission was 10 days (IQR 6–11 days), to mechanical ventilation (MV) was 11 days (IQR 7.75–13 days), to artificial liver plasma exchange was 12 days (IQR 9.75–14.75 days), and to extracorporeal membrane oxygenation (ECMO) was 22 days (IQR 17.5–30 days). Nine patients required high flow oxygen. Fourteen patients received MV. Six required ECMO. Nine received artificial liver plasma exchange. Mortality was 0 at day 28. Mortality was 0 at day 28 in our single-center study. Extracorporeal membrane oxygenation reduced the requirements for ventilator support. Artificial liver plasma exchange significantly reduced inflammatory cytokine levels. These supportive therapies helped to extend the patients’ survival times and increase the chance of follow-up treatments. Wolters Kluwer Health 2020-06-26 /pmc/articles/PMC7328989/ /pubmed/32590819 http://dx.doi.org/10.1097/MD.0000000000021012 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle 4900
Liu, Jian
Dong, Yong-Quan
Yin, Jie
He, Guojun
Wu, Xiaoxin
Li, Jianping
Qiu, Yunqing
He, Xuelin
Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study
title Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study
title_full Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study
title_fullStr Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study
title_full_unstemmed Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study
title_short Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study
title_sort critically ill patients with covid-19 with ecmo and artificial liver plasma exchange: a retrospective study
topic 4900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328989/
https://www.ncbi.nlm.nih.gov/pubmed/32590819
http://dx.doi.org/10.1097/MD.0000000000021012
work_keys_str_mv AT liujian criticallyillpatientswithcovid19withecmoandartificialliverplasmaexchangearetrospectivestudy
AT dongyongquan criticallyillpatientswithcovid19withecmoandartificialliverplasmaexchangearetrospectivestudy
AT yinjie criticallyillpatientswithcovid19withecmoandartificialliverplasmaexchangearetrospectivestudy
AT heguojun criticallyillpatientswithcovid19withecmoandartificialliverplasmaexchangearetrospectivestudy
AT wuxiaoxin criticallyillpatientswithcovid19withecmoandartificialliverplasmaexchangearetrospectivestudy
AT lijianping criticallyillpatientswithcovid19withecmoandartificialliverplasmaexchangearetrospectivestudy
AT qiuyunqing criticallyillpatientswithcovid19withecmoandartificialliverplasmaexchangearetrospectivestudy
AT hexuelin criticallyillpatientswithcovid19withecmoandartificialliverplasmaexchangearetrospectivestudy